Bedrijfsoverzicht
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise dedicated to the discovery and development of oncology medicines tailored for patients with tumors predicted to be sensitive to specific therapeutic agents. The company leverages its proprietary generative phosphoproteomics platform to facilitate this targeted approach, thereby operating within the healthcare sector and specifically the biotechnology industry, a field characterized by high research intensity and significant regulatory hurdles. The firm employs a workforce of 74 individuals and holds a market capitalization of $60.44 million, while its annual revenue and historical sales figures are not disclosed in the current reporting period. This specific valuation and revenue profile indicate that the company operates as a small-cap entity with limited current commercial traction, relying heavily on future product approvals and clinical trial successes to transition from a pre-commercial stage to a revenue-generating entity.
Financiële gezondheid
The company reports no disclosed revenue for the trailing twelve months, yet it recorded a net loss of $-77,905,000 and an EBITDA of $-82,758,000 during the same period. The substantial gap between the negligible revenue and the significant net loss reveals a cost structure driven entirely by research and development expenditures rather than commercial operations, which is typical for clinical-stage biotechnology firms. Free cash flow stands at $-39,543,248, indicating that the company is consuming cash reserves to fund its operations and clinical programs, thereby limiting immediate financial flexibility for external expansion or acquisitions. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, reflecting that the company has not yet achieved profitability from sales, as no commercial revenue is currently being generated to offset high fixed costs. The balance sheet maintains $118.58 million in cash against $2.71 million in debt, resulting in a debt-to-equity ratio of 2.41, which suggests a highly leveraged position relative to equity but one supported by substantial liquid assets. Despite the high debt-to-equity figure, the current ratio of 7.69 indicates robust short-term liquidity, as the company holds significantly more current assets than current liabilities, ensuring it can meet its obligations without immediate distress. However, the return on equity stands at -53.9% and return on assets at -32.2%, metrics that reveal management is currently unable to generate positive returns on shareholder capital or the asset base due to the heavy investment phase and lack of commercial income.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A due to the absence of earnings, while the forward P/E is reported at -0.84, a metric that implies the market prices the stock based on anticipated negative earnings or a reliance on non-earnings valuation drivers common in pre-revenue biotech stocks. The price-to-book ratio is 0.44, indicating that the market values the company at less than half of its book value, suggesting a deep discount relative to the tangible assets listed on the balance sheet rather than a market premium. The price-to-sales ratio is N/A given the lack of sales data, and the EV/EBITDA stands at 0.67, a low multiple that technically reflects the company's negative earnings and high cash balance rather than traditional valuation multiples applicable to profitable enterprises. The stock has traded between a 52-week low of $1.05 and a 52-week high of $3.56, placing the current trading price within a range that reflects significant volatility typical of small-cap biotechnology firms. The beta of 1.74 indicates that the stock is substantially more volatile than the broader market, moving 74% more than the benchmark in response to market shifts, which amplifies both potential gains and losses for holders during periods of market turbulence.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated sufficient commercial revenue to calculate meaningful growth rates or demonstrate a trajectory of earnings expansion. Consequently, the payout ratio is 0.0% and there is no dividend yield, meaning the company does not distribute income to shareholders but instead reinvests all available cash and capital into its clinical pipeline and research initiatives. Since the firm is non-dividend paying, the entire financial focus is directed toward sustaining operations and advancing drug candidates rather than providing immediate income streams to investors. The overall growth and income profile is currently defined by a complete absence of commercial earnings and dividends, with the company's value proposition resting entirely on the potential future success of its oncology medicines and the execution of its generative phosphoproteomics platform.